A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).

被引：0
|
作者：
Swaminathan, Mahesh
Dinardo, Courtney Denton
Maiti, Abhishek
Pemmaraju, Naveen
Ohanian, Maro
Daver, Naval Guastad
Garcia-Manero, Guillermo
Issa, Ghayas C.
Borthakur, Gautam
Ravandi-Kashani, Farhad
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Valero, Yesid Alvarado
Jabbour, Elias
Short, Nicholas James
Wierda, William G.
Jain, Nitin
Kornblau, Steven Mitchell
Kantarjian, Hagop M.
Konopleva, Marina
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Bellaire, TX USA
[4] Albert Einstein Coll Med, Montefiore Med Ctr, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6549
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS
    Mawad, Raya
    Becker, Pamela S.
    Hendrie, Paul
    Scott, Bart
    Wood, Brent L.
    Dean, Carol
    Sandhu, Vicky
    Deeg, Hans Joachim
    Walter, Roland
    Wang, Lixia
    Myint, Han
    Singer, Jack W.
    Estey, Elihu
    Pagel, John M.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (02) : 238 - 245
  • [32] A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (RR) FLT3-ITD acute myeloid leukemia (AML).
    Daver, Naval Guastad
    Zhang, Weiguo
    Graydon, Richard
    Dawra, Vikas
    Xie, Jingdong
    Kumar, Prasanna
    Andreeff, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
    Halpern, Anna B.
    Estey, Elihu H.
    Othus, Megan
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Chen, Tara L.
    Becker, Pamela S.
    Scott, Bart L.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Shadman, Mazyar
    Stirewalt, Derek L.
    Walter, Roland B.
    [J]. BLOOD, 2014, 124 (21)
  • [34] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
    Perez, Jorge M. Ramos
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Faderl, Stefan
    Sasaki, Koji
    Daver, Naval
    DiNardo, Courtney D.
    Masarova, Lucia
    Ferrajoli, Alessandra
    Jabbour, Elias
    Borthakur, Gautham
    Al Azzawi, Hind
    Pemmaraju, Naveen
    Konopleva, Marina
    Pierce, Sherry A.
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Alvarado, Yesid
    [J]. BLOOD, 2020, 136
  • [35] A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Zhang, Weiguo
    Graydon, Richard
    Dawra, Vikas K.
    Xie, Jingdong
    Kumar, Prasanna
    Andreeff, Michael
    [J]. BLOOD, 2019, 134
  • [36] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
    Perez, Jorge M. Ramos
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Benton, Christopher B.
    Faderl, Stefan
    Sasaki, Koji
    Naqvi, Kiran
    Cortes, Jorge E.
    Daver, Naval G.
    DiNardo, Courtney D.
    Jabbour, Elias
    Borthakur, Gautam M.
    Al Azzawi, Hind
    Pemmaraju, Naveen
    Konopleva, Marina Y.
    Pierce, Sherry A.
    Jain, Nitin
    Ohanian, Maro
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Alvarado, Yesid
    [J]. BLOOD, 2019, 134
  • [37] Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study
    Russo, Domenico
    Polverelli, Nicola
    Santarone, Stella
    Onida, Francesco
    Castagna, Luca
    Bramanti, Stefania
    Carella, A. M.
    Sorasio, Roberto
    Olivieri, Attilio
    Beltrami, Germana
    Curti, Antonio
    Vetro, Calogero
    Mancini, Valentina
    Terruzzi, Elisabetta
    Bernardi, Massimo
    Galieni, Piero
    Musto, Pellegrino
    Cerretti, Raffaella
    Giaccone, Luisa
    Skert, Cristina
    Borlenghi, Erika
    Farina, Mirko
    Leoni, Alessandro
    Radici, Vera
    Bernardi, Simona
    Vezzoli, Marika
    Calza, Stefano
    Gheorghiu, Angela
    Malagola, Michele
    Martino, Massimo
    Ciceri, Fabio
    [J]. BLOOD, 2023, 142
  • [38] a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Kadia, Tapan
    Ning, Jing
    Gonzalez, Graciela Nogueras
    Pierce, Sherry
    Kelly, Mary
    Zhang, Weiguo
    Gombos, Dan
    Kornblau, Steven
    Konopleva, Marina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Andreeff, Michael
    [J]. BLOOD, 2017, 130
  • [39] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Jabbour, Elias
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Pierce, Sherry
    Gombos, Dan
    Komblau, Steven
    Konopleva, Marina
    Kelly, Mary
    Borthakur, Gautam
    Zhang, Weiguo
    Cortes, Jorge
    Kantarjian, Hagop
    Andreeffl, Michael
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8
  • [40] A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Nazha, Aziz
    Kantarjian, Hagop
    Borthakur, Gautam
    Kadia, Tapan M.
    Faderl, Stefan
    Ravandi, Farhad
    Estrov, Zeev
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Cortes, Jorge E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345